2-甲基-5-苯并噻唑乙酸 | 103264-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-甲基-5-苯并噻唑乙酸
• 英文名称: 2-Methyl-5-carboxymethyl-benzthiazol
• 英文别名: 2-Methyl-6-carboxymethyl-benzthiazol；(2-methyl-benzothiazol-5-yl)-acetic acid；2-(2-Methyl-1,3-benzothiazol-5-yl)acetic acid
• CAS: 103264-09-1
• 化学式: C₁₀H₉NO₂S
• mdl: MFCD00551810
• 分子量: 207.253
• InChiKey: IWYBEKPGSYQVFQ-UHFFFAOYSA-N

物化性质

• 熔点：
  198 °C
• 沸点：
  389.1±17.0 °C(Predicted)
• 密度：
  1.381±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 2-甲基-5-苯并噻唑乙酸 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain

  摘要：

  Rhodesain, the major cathepsin L-like cysteine protease in the protozoan Trypanosoma brucei rhodesiense, the causative agent of African sleeping sickness, is a well-validated drug target. In this work, we used a fragment-based approach to identify inhibitors of this cysteine protease, and identified inhibitors of T. brucei. To discover inhibitors active against rhodesain and T. brucei, we screened a library of covalent fragments against rhodesain and conducted preliminary SAR studies. We envision that in vitro enzymatic assays will further expand the use of the covalent tethering method, a simple fragment-based drug discovery technique to discover covalent drug leads. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.08.074
• 作为产物：
  描述：

  2-(2-甲基-1,3-苯并噻唑-5-基)乙腈 在 盐酸 作用下， 反应 5.0h， 生成 2-甲基-5-苯并噻唑乙酸
  参考文献：
  名称：

  Zubarovskii,V.M.; Khodot,G.P., Journal of general chemistry of the USSR, 1960, vol. 30, p. 1268 - 1272

  摘要：

  DOI：

文献信息

• BENZAZOLES: BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES
  申请人：Zeneca Limited

  公开号：EP1100798A1

  公开（公告）日：2001-05-23
• BENZAZOLE, BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES
  申请人：Syngenta Limited

  公开号：EP1100798B1

  公开（公告）日：2002-09-18
• US6544989B2
  申请人：——

  公开号：US6544989B2

  公开（公告）日：2003-04-08
• [EN] BENZAZOLES: BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES<br/>[FR] DERIVES DE BENZOXAZOLE, BENZTHIAZOLE ET BENZIMIDAZOLE
  申请人：ZENECA LTD

  公开号：WO2000006566A1

  公开（公告）日：2000-02-10

  A compund of formula (I) wherein X is O or S; n is 0 or 1; Y is O, S or NR7; R1 is hydrogen, halogen, C¿1-6? aklyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkylthio, C1-6 haloalkylthio, C3-6 cycloalkyl, C1-6 alkoxy(C1-6)alkyl or SF5; R?2¿ is hydrogen, halogen, C¿1-6? alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkylthio, C1-6 haloalkylthio, C1-6 alkylsulfinyl, C1-6 haloalkylsulfinyl, C1-6 alkylsulfonyl, C1-6 haloalkylsulfonyl, C1-6 haloalkyl, cyano, nitro, CHO, CH=NOR?5, C¿1-6 alkylcarbonyl, C1-6 alkoxycarbonyl or SF5; or together R?1 and R2¿ form a five or six membered saturated or unsturated carbocyclic ring, optionally substituted processes for preparing these compounds, compositions comprising them, methods of using them to combat fungal diseases and methods of using them to combat or control insect, acarine, mollusc and nematode pests.
• Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain
  作者：Danielle McShan、Stefan Kathman、Brittiney Lowe、Ziyang Xu、Jennifer Zhan、Alexander Statsyuk、Ifedayo Victor Ogungbe

  DOI：10.1016/j.bmcl.2015.08.074

  日期：2015.10

  Rhodesain, the major cathepsin L-like cysteine protease in the protozoan Trypanosoma brucei rhodesiense, the causative agent of African sleeping sickness, is a well-validated drug target. In this work, we used a fragment-based approach to identify inhibitors of this cysteine protease, and identified inhibitors of T. brucei. To discover inhibitors active against rhodesain and T. brucei, we screened a library of covalent fragments against rhodesain and conducted preliminary SAR studies. We envision that in vitro enzymatic assays will further expand the use of the covalent tethering method, a simple fragment-based drug discovery technique to discover covalent drug leads. (C) 2015 Elsevier Ltd. All rights reserved.